ELAVL1 and prostate carcinoma: The immunohistochemistry analysis showed higher protein level of HuR in tumor tissues than in non-tumor tissues, including breast cancer (S1B Fig), cervical cancer (S1C Fig), colorectal cancer (S1D Fig), liver cancer (S1E Fig), lung cancer (S1F Fig), ovarian cancer (S1G Fig), pancreatic cancer (S1H Fig), prostate cancer (S1I Fig), and renal cancer (S1J Fig).